Educational clinical resource
Prenatal genetic screening and diagnostic testing explained
Understand the difference between NIPT and other screening tests, CVS or amniocentesis, and laboratory tests such as karyotype, microarray, and exome.
- 01Ultrasound
- 02Placenta & growth
- 03Multiple pregnancy
- 04Prenatal genetics
How to navigate Prenatal genetic screening and diagnostic testing explained
An educational path from the first question to the next step. It does not replace individual assessment.
- 01Frame the decision
Define the exact choice, timing, and what cannot safely wait.
- 02Gather the evidence
Review diagnosis, severity, uncertainty, and the most relevant external evidence.
- 03Compare the options
Set benefits, burdens, limitations, and alternatives side by side.
- 04Include family priorities
Discuss values, practical needs, and acceptable trade-offs without pressure.
- 05Document the plan
Record the decision, safety net, responsible team, and next review point.
Visual decision pathway
Screening and diagnosis are different routes
Start with the clinical question, then choose whether probability or a diagnostic answer is needed.
- QuestionDefine the purpose
General risk assessment, abnormal screening, fetal finding or a known familial condition?
- RouteChoose screening or sampling
Screening changes probability; CVS or amniocentesis obtains material for diagnosis.
- ResolutionSelect the laboratory test
Karyotype, microarray, targeted testing or exome answer different questions.
- MeaningInterpret before acting
Integrate phenotype, test limits, uncertain variants, timing and what the result can change.
Direct answer
Prenatal screening estimates the chance of selected conditions; diagnostic testing examines fetal or placental genetic material to determine whether a condition is present. NIPT, combined first-trimester screening, and ultrasound are screening approaches. CVS and amniocentesis obtain samples that laboratories can analyse with tests such as karyotype, chromosomal microarray, targeted gene testing, or exome sequencing.
A low-chance NIPT result substantially reduces the probability of the common trisomies included in that test, but it does not prove that the fetus has no structural, chromosomal, or genetic condition. A high-chance result is also not the same as a diagnosis and generally needs counselling and consideration of confirmatory diagnostic testing.
Screening and sampling are different decisions
NIPT analyses placental DNA fragments circulating in maternal blood. Its performance varies by condition and clinical context. Ultrasound can identify structural findings and markers that may change the interpretation of a screening result. Neither replaces the other.
CVS usually samples placental tissue earlier in pregnancy. Amniocentesis samples amniotic fluid later. The most appropriate procedure depends on gestational age, placental position, the clinical question, the possibility of placental mosaicism, and patient preference after counselling. Procedure-related risks should be discussed using the operator’s current evidence and local pathway rather than a generic internet number.
The laboratory test determines the level of resolution
A sample is only the beginning. Karyotype assesses chromosome number and large structural changes. Chromosomal microarray can identify smaller gains and losses of genetic material. Targeted testing looks for a specific condition suggested by family history or fetal phenotype. Exome sequencing examines many coding regions and may be considered in selected fetuses with structural abnormalities when standard testing has not provided an answer.
Greater resolution does not guarantee certainty. Tests can return a pathogenic finding, a normal result within the method’s limits, a variant of uncertain significance, or an incidental result with implications beyond the immediate pregnancy. Pre-test counselling should explain what results are possible and which findings the patient wishes to receive.
A better decision framework
Start with the question: Is the goal general risk assessment, clarification of an abnormal screen, investigation of a fetal finding, or testing for a known familial condition? Then consider timing, what each result could change, the limitations of the test, procedural risk, turnaround time, and the patient’s values. The technically most extensive test is not automatically the most appropriate first test.